Use of Oral Antidiabetic Agents in Hospitalized Patients With Diabetes

Who is this study for? Adult patients with Diabetes
What treatments are being studied? Insulin
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug, Device
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Males or females, age 18-80 years admitted to a general medicine and surgery services

• Known history of T2D receiving OADs either as monotherapy or in combination therapy

• Admission BG \< 250 mg/dl or randomization BG \<250 mg/dl and not receiving basal insulin

• Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c \<7.5% within the past three months

• HbA1c \<10%

Locations
United States
Georgia
Emory University Hospital
RECRUITING
Atlanta
Emory University Hospital Midtown
RECRUITING
Atlanta
Grady Memorial Hospital
RECRUITING
Atlanta
Contact Information
Primary
Maya Fayfman, MD
maya.fayfman@emory.edu
404-778-1664
Time Frame
Start Date: 2020-08-07
Estimated Completion Date: 2026-05
Participants
Target number of participants: 260
Treatments
Experimental: Oral Anti-diabetes Drugs (OADs) alone
OADs will be continued at same outpatient dosage unless contraindicated
Active_comparator: Basal bolus insulin
Basal insulin with glargine or detemir and rapid-acting insulin (lispro/aspart) will be used as per the hospital formulary. OADs and non-insulin injectable antidiabetic medication will be discontinued on admission.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: Emory University

This content was sourced from clinicaltrials.gov